Susquehanna Fundamental Investments LLC Takes $572,000 Position in Nuvation Bio Inc. (NYSE:NUVB)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Nuvation Bio Inc. (NYSE:NUVB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 215,198 shares of the company’s stock, valued at approximately $572,000. Susquehanna Fundamental Investments LLC owned approximately 0.06% of Nuvation Bio at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NUVB. FMR LLC boosted its position in shares of Nuvation Bio by 54.9% during the 4th quarter. FMR LLC now owns 45,285,572 shares of the company’s stock worth $120,460,000 after acquiring an additional 16,046,701 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Nuvation Bio by 45.4% in the 4th quarter. Vanguard Group Inc. now owns 15,732,567 shares of the company’s stock valued at $41,849,000 after purchasing an additional 4,913,820 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Nuvation Bio by 22.9% in the 4th quarter. Geode Capital Management LLC now owns 4,951,195 shares of the company’s stock valued at $13,174,000 after purchasing an additional 922,503 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Nuvation Bio by 39.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,945,983 shares of the company’s stock worth $5,176,000 after buying an additional 551,968 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Nuvation Bio by 8.3% during the 4th quarter. Wellington Management Group LLP now owns 676,024 shares of the company’s stock worth $1,798,000 after buying an additional 52,051 shares during the last quarter. Institutional investors own 61.67% of the company’s stock.

Insiders Place Their Bets

In other Nuvation Bio news, CEO David Hung purchased 300,000 shares of the firm’s stock in a transaction on Monday, April 7th. The stock was purchased at an average cost of $1.62 per share, for a total transaction of $486,000.00. Following the acquisition, the chief executive officer now owns 58,781,054 shares in the company, valued at approximately $95,225,307.48. The trade was a 0.51 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 29.93% of the company’s stock.

Analysts Set New Price Targets

NUVB has been the subject of several research analyst reports. JMP Securities initiated coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set a “market outperform” rating and a $6.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a research note on Thursday, March 27th. Jones Trading started coverage on shares of Nuvation Bio in a research note on Wednesday, March 12th. They set a “buy” rating and a $10.00 target price on the stock. Citizens Jmp started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $6.00 price target for the company. Finally, Citigroup initiated coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They set an “outperform” rating on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.83.

Nuvation Bio Price Performance

Shares of NUVB opened at $2.46 on Friday. The business has a 50-day moving average of $1.96 and a 200-day moving average of $2.37. The company has a market capitalization of $833.15 million, a price-to-earnings ratio of -1.13 and a beta of 1.47. Nuvation Bio Inc. has a 1 year low of $1.54 and a 1 year high of $3.97.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.